Arizona State Retirement System grew its position in shares of Catalent Inc (NYSE:CTLT) by 35.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 95,638 shares of the company’s stock after purchasing an additional 24,852 shares during the period. Arizona State Retirement System’s holdings in Catalent were worth $3,929,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in CTLT. American Century Companies Inc. raised its stake in shares of Catalent by 755.3% in the fourth quarter. American Century Companies Inc. now owns 2,631,643 shares of the company’s stock valued at $108,108,000 after acquiring an additional 2,323,971 shares in the last quarter. Eagle Asset Management Inc. raised its stake in shares of Catalent by 290.9% in the third quarter. Eagle Asset Management Inc. now owns 1,153,710 shares of the company’s stock valued at $47,636,000 after acquiring an additional 858,600 shares in the last quarter. Emerald Advisers Inc. PA raised its stake in shares of Catalent by 1,072.2% in the third quarter. Emerald Advisers Inc. PA now owns 604,207 shares of the company’s stock valued at $24,120,000 after acquiring an additional 552,663 shares in the last quarter. Emerald Mutual Fund Advisers Trust acquired a new stake in shares of Catalent in the third quarter valued at $18,420,000. Finally, Hood River Capital Management LLC acquired a new stake in shares of Catalent in the fourth quarter valued at $16,283,000. Institutional investors and hedge funds own 99.82% of the company’s stock.
Several equities analysts recently commented on CTLT shares. Goldman Sachs Group started coverage on Catalent in a report on Wednesday, January 24th. They issued a “buy” rating and a $50.00 target price on the stock. Royal Bank of Canada set a $48.00 target price on Catalent and gave the company a “buy” rating in a report on Monday, February 5th. Stephens lowered Catalent from an “overweight” rating to an “equal weight” rating in a report on Tuesday, February 6th. Zacks Investment Research raised Catalent from a “hold” rating to a “buy” rating and set a $48.00 target price on the stock in a report on Wednesday, January 17th. Finally, Bank of America increased their target price on Catalent from $47.00 to $49.00 and gave the company a “buy” rating in a report on Tuesday, February 6th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Catalent has an average rating of “Buy” and a consensus price target of $45.70.
Catalent Inc (NYSE:CTLT) opened at $41.75 on Thursday. The company has a market capitalization of $5,640.00, a price-to-earnings ratio of 46.39, a P/E/G ratio of 2.46 and a beta of 1.47. The company has a quick ratio of 1.78, a current ratio of 2.22 and a debt-to-equity ratio of 2.66. Catalent Inc has a twelve month low of $27.48 and a twelve month high of $47.87.
Catalent (NYSE:CTLT) last issued its quarterly earnings data on Monday, February 5th. The company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.10. The company had revenue of $606.30 million for the quarter, compared to analyst estimates of $565.05 million. Catalent had a return on equity of 23.85% and a net margin of 3.03%. The business’s quarterly revenue was up 25.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.27 earnings per share. equities analysts expect that Catalent Inc will post 1.53 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.tickerreport.com/banking-finance/3229645/arizona-state-retirement-system-grows-holdings-in-catalent-inc-ctlt.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.